Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KYAW ZIN THEIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1558772889
CMS profile
8789909
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$20,358.63

234 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KYAW ZIN THEIN

NPI 1558772889 · CMS profile ID 8789909

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558772889?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KYAW ZIN THEIN, NPI 1558772889, CMS profile ID 8789909. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558772889?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). KYAW ZIN THEIN, NPI 1558772889, CMS profile ID 8789909. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558772889?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
KYAW ZIN THEIN, NPI 1558772889, CMS profile ID 8789909, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558772889?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

234 matching records · $20,358.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 234 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 234.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $4.8507/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197084977 CMS
Daiichi Sankyo Inc. $10.7807/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197089949 CMS
BeOne Medicines USA, Inc. $16.1507/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202887994 CMS
GlaxoSmithKline, LLC. $10.1507/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190504437 CMS
AstraZeneca Pharmaceuticals LP $17.2707/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206277358 CMS
Caris MPI, Inc. $22.5107/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234288228 CMS
ARRAY BIOPHARMA INC $11.9106/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229118836 CMS
PFIZER INC. $9.7806/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228903633 CMS
Stemline Therapeutics Inc. $14.9006/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244097465 CMS
Daiichi Sankyo Inc. $124.4306/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197020125 CMS
Daiichi Sankyo Inc. $13.4206/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197082705 CMS
Exelixis Inc. $34.8506/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218797567 CMS
Novartis Pharmaceuticals Corporation $14.7206/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200402809 CMS
Daiichi Sankyo Inc. $1.2106/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197080203 CMS
Merck Sharp & Dohme LLC $27.1106/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238054201 CMS
Agios Pharmaceuticals, Inc. $22.1406/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253260418 CMS
AstraZeneca Pharmaceuticals LP $14.8206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206538362 CMS
Daiichi Sankyo Inc. $10.9306/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197100843 CMS
Daiichi Sankyo Inc. $4.8006/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197082265 CMS
Genmab U.S., Inc. $21.6706/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235921524 CMS
SERVIER PHARMACEUTICALS LLC $23.8706/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229103477 CMS
Merck Sharp & Dohme LLC $24.2106/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238319656 CMS
Novartis Pharmaceuticals Corporation $17.2606/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200402797 CMS
Pharmacosmos Therapeutics Inc. $144.4206/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250731336 CMS
Caris MPI, Inc. $15.0906/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234288225 CMS
Daiichi Sankyo Inc. $1.2906/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197100929 CMS
AstraZeneca Pharmaceuticals LP $15.1506/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206372655 CMS
Coherus Oncology, Inc. $2,250.0006/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1235235342 CMS
Coherus Oncology, Inc. $138.4206/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235235346 CMS
Daiichi Sankyo Inc. $13.5105/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197071059 CMS
Daiichi Sankyo Inc. $4.7605/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197080149 CMS
Novartis Pharmaceuticals Corporation $28.4805/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200402799 CMS
ARRAY BIOPHARMA INC $18.7805/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228925337 CMS
Exelixis Inc. $34.8505/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218797565 CMS
Daiichi Sankyo Inc. $1.4905/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197071487 CMS
PFIZER INC. $3.9905/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231529736 CMS
Daiichi Sankyo Inc. $10.3105/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197071519 CMS
PFIZER INC. $16.1605/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231298763 CMS
SOBI, INC $20.4605/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240259801 CMS
AstraZeneca Pharmaceuticals LP $21.8405/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207048411 CMS
Novartis Pharmaceuticals Corporation $12.0405/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200402805 CMS
Incyte Corporation $26.2405/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225991641 CMS
Daiichi Sankyo Inc. $4.7605/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197064243 CMS
Daiichi Sankyo Inc. $8.4405/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197071459 CMS
Merck Sharp & Dohme LLC $11.5205/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238361595 CMS
BeOne Medicines USA, Inc. $31.7005/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202887996 CMS
Sumitomo Pharma America, Inc. $14.9905/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176728183 CMS
Daiichi Sankyo Inc. $1.5605/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197071061 CMS
Caris MPI, Inc. $11.1505/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234288221 CMS
Lilly USA, LLC $15.6205/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186739953 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $344.40 7
PY2023 $4,629.32 69
PY2024 $22,212.28 209
PY2025 $20,358.63 234

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $225,123.53 52
PY2024 Principal investigator $200,218.22 82
PY2023 Principal investigator $45,299.10 3
PY2022 Principal investigator $231,000.07 4
PY2021 Principal investigator $181,268.12 10
PY2020 Principal investigator $16,126.90 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination with Bevacizumab in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202535209
Principal investigator 1 Merck Sharp & Dohme LLC $12,322.38 12/31/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 No dispute reported 06/30/2026 1232927307
Principal investigator 1 Coherus Oncology, Inc. $21,260.00 12/23/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers
CHS11402 No dispute reported 06/30/2026 1235252596
Principal investigator 1 ABBVIE INC. $101.00 11/26/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525402
Principal investigator 1 ABBVIE INC. $551.00 11/26/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525406
Principal investigator 1 ABBVIE INC. $823.00 11/24/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525148
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,146.20 10/24/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1185547949
Principal investigator 1 ABBVIE INC. $1,798.00 10/03/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202513195
Principal investigator 1 ABBVIE INC. $166.83 09/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512624
Principal investigator 1 ABBVIE INC. $150.75 09/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512638
Principal investigator 1 ABBVIE INC. $452.25 09/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512640
Principal investigator 1 ABBVIE INC. $1,200.00 07/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499988
Principal investigator 1 PFIZER INC. $1,008.64 07/28/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228769869
Principal investigator 1 ABBVIE INC. $1,742.00 07/23/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499266
Principal investigator 1 ABBVIE INC. $583.57 06/26/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492927
Principal investigator 1 ABBVIE INC. $452.25 06/26/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492929
Principal investigator 1 Amgen Inc. $13,027.00 06/26/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion No dispute reported 06/30/2026 1246649864
Principal investigator 1 Amgen Inc. $1,552.00 06/25/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) No dispute reported 06/30/2026 1246649849
Principal investigator 1 Amgen Inc. $2,120.00 06/13/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) No dispute reported 06/30/2026 1246640489
Principal investigator 1 PFIZER INC. $6,551.62 06/09/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228777714
Principal investigator 1 ABBVIE INC. $396.64 05/05/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202481067
Principal investigator 1 ABBVIE INC. $3,484.00 05/05/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202481069
Principal investigator 1 ABBVIE INC. $1,742.00 05/05/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202481071
Principal investigator 1 ABBVIE INC. $1,265.00 04/30/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480385
Principal investigator 1 Servier BioInnovation $1,500.00 04/28/2025 Non-covered Recipient Entity
Allison Curtis Kingsley Meoz Michael and Sanchez Prof. Corp.
Phase 1b/2 platform study of select immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) No dispute reported 06/30/2026 1235967389
Principal investigator 1 Servier BioInnovation $2,500.00 04/28/2025 Non-covered Recipient Entity
Allison Curtis Kingsley Meoz Michael and Sanchez Prof. Corp.
Phase 1b/2 platform study of select immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) No dispute reported 06/30/2026 1235967391
Principal investigator 1 Servier BioInnovation $8,500.00 04/28/2025 Non-covered Recipient Entity
Allison Curtis Kingsley Meoz Michael and Sanchez Prof. Corp.
Phase 1b/2 platform study of select immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) No dispute reported 06/30/2026 1235967393
Principal investigator 1 Servier BioInnovation $750.00 04/28/2025 Non-covered Recipient Entity
Allison Curtis Kingsley Meoz Michael and Sanchez Prof. Corp.
Phase 1b/2 platform study of select immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) No dispute reported 06/30/2026 1235967395
Principal investigator 1 PFIZER INC. $3,924.48 04/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228781201
Principal investigator 1 ABBVIE INC. $2,686.00 04/03/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468695
Principal investigator 1 ABBVIE INC. $3,466.00 04/02/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468366
Principal investigator 1 ABBVIE INC. $3,739.94 03/24/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465603
Principal investigator 1 PFIZER INC. $47,840.50 02/10/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228795752
Principal investigator 1 ABBVIE INC. $3,396.90 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442208
Principal investigator 1 ABBVIE INC. $1,425.09 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442212
Principal investigator 1 ABBVIE INC. $2,127.25 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442216
Principal investigator 1 ABBVIE INC. $1,644.85 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442221
Principal investigator 1 ABBVIE INC. $3,859.20 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442225
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442228
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442566
Principal investigator 1 ABBVIE INC. $2,024.74 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442570
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442575
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442604
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442606
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442609
Principal investigator 1 ABBVIE INC. $1,707.83 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442613
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442618
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442621
Principal investigator 1 ABBVIE INC. $1,057.93 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442625
Principal investigator 1 ABBVIE INC. $1,857.91 01/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442629
Principal investigator 1 Amgen Inc. $1,755.50 01/27/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion No dispute reported 06/30/2026 1246640491
Principal investigator 1 ABBVIE INC. $2,000.00 01/22/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440879